Here are the 8-K filings from CNBX Pharmaceutical Inc (CNBX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow CNBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNBX filings page.
CNBX Pharmaceuticals Inc. dismissed Elkana Amitai CPA as its independent registered public accounting firm effective September 28, 2026, and engaged Vilki & Co. on that date as its new independent accounting firm as of and for the year ended August 31, 2026. CNBX said the change was not the result of a disagreement. It reported no disagreements or reportable events during the years ended August 31, 2025 and 2026 through the dismissal date. The former firm's audit reports for the fiscal years ended August 31, 2024 and 2025 included explanatory paragraphs indicating substantial doubt about CNBX's ability to continue as a going concern; the reports contained no adverse or disclaimer opinions and were not otherwise qualified or modified.
CNBX Pharmaceuticals Inc. entered into a new short-term financing arrangement. On March 10, 2026, the company executed a non-convertible promissory note with 3i L.P. for $45,000. The note bears simple interest at 5% per year and matures on July 1, 2026.
The company plans to use the proceeds for immediate working capital needs and operating expenditures. This is a relatively small, fixed-rate debt instrument aimed at supporting near-term liquidity rather than long-term expansion.